ELRIG Drug Discovery 2022 (London, 2022)

The role of platelet function and viability testing in addressing observations of suspected drug-induced thrombocytopenia. Please click here for a .pdf of the poster.

Platelet Society Annual Meeting (Hull, 2022)

Application of platelet testing in drug discovery. Please click here for a .pdf of the poster.

ELRIG Drug Discovery 2021 (Liverpool, 2021)

Platelet function testing in drug discovery projects: considerations and challenges. Please click here for a .pdf of the poster.

ELRIG Drug Discovery 2019 (Liverpool, 2019)

Platelet aggregation and activation assessed in small volumes of fixed whole blood – high throughput assays for testing the effects of pharmacological compounds on platelet function. Please click here for a .pdf of the poster.

ELRIG Drug Discovery 2019 (Liverpool, 2019)

A simple one-step approach for measuring phosphorylated VASP in blood and platelet rich plasma by flow cytometry. Please click here for a .pdf of the poster.


Humphries RG et al (1994). FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T‐purinoceptors. British Journal of Pharmacology, 113(3): 1057-1063. 

DOI: 10.1111/j.1476-5381.1994.tb17100.x  

Jarvis GE et al (2000). ADP can induce aggregation of human platelets via both P2Y1 and P2T receptors. British Journal of Pharmacology, 129(2): 275-282. 

DOI: 10.1038/sj.bjp.0703046

Zhao L et al (2001). Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.  British Journal of Pharmacology, 134(2): 353-358.

DOI: 10.1038/sj.bjp.0704248

Zhao L et al (2003). The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Current Medical Research and Opinion, 19(3): 178-186. 

DOI: 10.1185/030079903125001721

Van Giezen JJJ and Humphries RG (2005). Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. In Seminars in thrombosis and hemostasis, 31(2): 195-204. 

DOI: 10.1055/s-2005-869525

Husted S et al (2006). Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. European Heart Journal, 27(9): 1038-1047.

DOI: 10.1093/eurheartj/ehi754

Springthorpe B et al (2007). From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorganic & medicinal chemistry letters, 17(21): 6013-6018. 

DOI: 10.1016/j.bmcl.2007.07.057

Heptinstall S et al (2008). DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease. Platelets, 19(8): 605-613.

DOI: 10.1080/09537100802351073

Manolopoulos P et al (2008). Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: A new finding that may influence the design of anti-thrombotic agents. Platelets, 19(2): 134-145. 

DOI: 10.1080/09537100701708498

Iyú D et al (2011). P2Y12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets, 22(7): 504-515.

DOI: 10.3109/09537104.2011.576284

Fox SC et al (2013). Effects on platelet function of an EP3 receptor antagonist used alone and in combination with P2Y12 antagonist both in vitro and ex vivo in human volunteers. Platelets, 24(5): 392-400. 

DOI: 10.3109/09537104.2011.576284

Lordkipanidze MD et al (2013). Development of a novel high throughput 96 well plate-based whole blood assay for investigation of platelet function in healthy volunteers and patients with clinically diagnosed bleeding disorders. – page 763

Glenn JR et al (2014). ‘VASPFix’ for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists. Thromb Haemost, 111(3): 539-548. 

DOI: 10.1160/TH13-07-0581 

Thomas M et al (2014). A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel. Platelets, 25(8), pp.612-618. 

DOI: 10.3109/09537104.2013.863858

Afghani M et al (2015). A new approach to measuring platelet aggregation and platelet-leucocyte conjugate formation in a small volume of fixed whole blood. – page 655

Germanovich et al (2015). Comparison of the Biocytex and the VASPFix assays of VASP phosphorylation in coronary-artery disease patients treated with clopidogrel plus aspirin. – page784

Bath P et al (2018). Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders. Platelets, 29(5): 425-430. 

DOI: 10.1080/09537104.2018.1445839

Fox SC et al (2019).  How does measurement of platelet P-selectin compare with other methods of measuring platelet function as a means of determining the effectiveness of antiplatelet therapy? Platelets, 30(3): 290-295. 

DOI: 10.1080/09537104.2018.1434311 

Get in touch

Contact us